<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01620762</url>
  </required_header>
  <id_info>
    <org_study_id>CP007</org_study_id>
    <nct_id>NCT01620762</nct_id>
  </id_info>
  <brief_title>Phase III Cat-PAD Study</brief_title>
  <official_title>A Double-Blind, Randomised, Placebo-Controlled Multi-Centre Field Study to Assess the Efficacy and Safety of Cat-PAD Peptide Immunotherapy in Cat Allergic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Circassia Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>inVentiv Health Clinical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pharm-Olam International</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Circassia Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the treatment effect of two treatment regimens of
      Cat-PAD vs placebo and to evaluates the treatment effect of Cat-PAD on symptoms, rescue
      medication usage and Quality of Life.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Combined Score in Cat-PAD Treatment Groups Compared With Placebo</measure>
    <time_frame>52-54 weeks after randomisation</time_frame>
    <description>The primary endpoint was the mean Combined Score (CS) during the Post Administration Collection Period 3 (52-54 weeks after randomisation) in the Cat-PAD treatment groups compared with the mean CS in the placebo group.
CS = Total Rhinoconjunctivitis Symptom Score (TRSS) (0-24/8) + Rescue Medication Score (RMS) (0-3). Eight symptoms are defined in the TRSS, 4 nasal symptoms: runny nose, sneezing; blocked nose, and itchy nose and 4 ocular symptoms: itchy eyes; watery eyes; red eyes, and sore eyes. Each symptom was rated in severity on a score of 0-3 (0=absent, 3=severe) and the TRSS was divided by the number of symptoms (8) to provide an average score per symptom of 0-3.
For RMS the score was allocated according Didier et al where RMS = 0 (no allergy rescue medication use per day) to RMS = 3 (at least one dose of systemic corticosteroid per day). The RMS score was not additive, and therefore the maximum RMS was 3 and the maximum CS was 6.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean TRSS</measure>
    <time_frame>52-54 weeks after randomisation</time_frame>
    <description>Mean Total Rhinoconjunctivitis Symptom Score (TRSS) in Cat-PAD treatment groups compared with placebo.
Eight symptoms are defined in the TRSS, 4 nasal symptoms: runny nose, sneezing; blocked nose, and itchy nose and 4 ocular symptoms: itchy eyes; watery eyes; red eyes, and sore eyes. Each symptom was rated in severity on a score of 0-3 (0. absent; 1. mild, barely noticeable; 2. moderate, annoying/troublesome; 3. severe, very annoying/very troublesome), therefore TRSS could range from 0 to 24. Higher TRSS reflected more severe symptom scores. Symptoms were scored daily for a period of approximately 3 weeks. 52-54 weeks after randomisation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Daily TNSS in Cat-PAD Compared With Placebo</measure>
    <time_frame>52-54 weeks after randomisation</time_frame>
    <description>TNSS (Total nasal symptom score) was the sum of all the nasal symptom scores (runny nose; sneezing; blocked nose; itchy nose) and could range from 0 to 12. Higher TNSS reflected more severe symptoms.
Subjects rated the severity of each symptom over the last 24 hours as follows: 0. absent; 1. mild, barely noticeable; 2. moderate, annoying/troublesome; 3. severe, very annoying/very troublesome. Symptoms were scored daily for a period of approximately 3 weeks. 52-54 weeks after randomisation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Daily TOSS in Cat-PAD Compared to Placebo</measure>
    <time_frame>52-54 weeks after randomisation</time_frame>
    <description>Mean daily Total Ocular Symptom Score (TOSS) in Cat-PAD treatment groups compared to placebo groups
TOSS was the sum of all the ocular symptom scores (itchy eyes; watery eyes; red eyes; sore eyes) and could range from 0 to 12. Higher TOSS reflected more severe symptoms.
Subjects rated the severity of each symptom over the last 24 hours as follows: 0. absent; 1. mild, barely noticeable; 2. moderate, annoying/troublesome; 3. severe, very annoying/very troublesome. Symptoms were scored daily for a period of approximately 3 weeks. 52-54 weeks after randomisation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean RMS in Cat-PAD Compared With Placebo</measure>
    <time_frame>52-54 weeks after randomisation</time_frame>
    <description>Mean RMS (Rescue medication score) in Cat-PAD treatment groups compared with placebo groups.
The use of rhinoconjunctivitis rescue medications was recorded by the subject on a daily basis just before bedtime for approximately 21 days, 52-54 weeks after randomisation and was scored based on a previously published system as follows: 0 = no allergy rescue medication used per day; 0.5 = at least one dose of antihistamine eye drops used per day; 1 = at least one dose of oral antihistamine used per day; 2 = at least one dose of intranasal corticosteroid used per day; 3 = at least one dose of systemic corticosteroid used per day. The score was according to the highest level of rescue medication used and was not additive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean RQLQ Score in Cat-PAD Compared With Placebo</measure>
    <time_frame>52-54 weeks after randomisation</time_frame>
    <description>The RQLQ (Rhinoconjunctivitis Quality of Life Questionnaire) was completed by subjects at the end of the study (52-54 weeks after randomisation).
The RQLQ is a validated method of assessing quality of life and has 28 questions in seven domains (activity limitation, sleep problems, nasal symptoms, eye symptoms, non-nasal/eye symptoms, practical problems and emotional function). Subjects recalled how their rhinoconjunctivitis had been during the last week and responded to each question on a seven-point scale (0 = no impairment, 6 = maximum impairment). The questions were equally weighted, and the RQLQ score was the mean of the 28 questions and could range from zero to six.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days With no Moderate or Severe TRSS Symptoms Without Rescue Medication Use</measure>
    <time_frame>52-54 week after randomisaiton</time_frame>
    <description>The number of well days, i.e., days with no moderately or severely annoying symptoms and with no rescue medication used was calculated for all subjects over a period of approximately 21 days, 52-54 weeks after randomisation.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1408</enrollment>
  <condition>Rhinoconjunctivitis</condition>
  <arm_group>
    <arm_group_label>Cat-Pad Treatment 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cat-PAD Treatment 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cat-PAD Treatment 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cat-PAD Treatment regimen 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cat-PAD</intervention_name>
    <description>1 dose every 4 weeks</description>
    <arm_group_label>Cat-Pad Treatment 1</arm_group_label>
    <arm_group_label>Cat-PAD Treatment 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 dose every 4 weeks</description>
    <arm_group_label>Cat-PAD Treatment 2</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Male or female, aged 12-65 years.

          -  Moderate to severe rhinoconjunctivitis on exposure to cats for at least 2 years.

          -  Subjects may optionally also have GINA Step 1 controlled asthma.

          -  Positive skin prick test to cat hair.

          -  Cat dander specific IgE â‰¥0.35 kU/L.

        Exclusion Criteria

          -  Asthma falling under the GINA definitions &quot;partly controlled&quot; and &quot;uncontrolled&quot; or
             Steps 2 to 5.

          -  FEV1 &lt;80% of predicted.

          -  Clinically significant confounding symptoms of allergy to seasonal allergens during
             the final evaluation period.

          -  Skin prick test 5 mm greater than the negative control to perennial allergens or
             animal dander (other than cat) which cannot be avoided during the study.

          -  Significant symptoms of another clinically relevant illness that is likely to affect
             scoring of rhinoconjunctivitis symptoms.

          -  Clinically relevant abnormalities detected on physical examination.

          -  History of severe drug allergy, severe angioedema or anaphylactic reaction to food.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harold Nelson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jewish National Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Rolling Hills Estates</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eagle</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Forrest</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iowa</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bozeman</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fremont</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ocean Township</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Corning</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newburgh</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minot</city>
        <state>North Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sylvania</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lake Oswego</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Blue Bell</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glen Allen</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Burlington</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warrenton</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenfield</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Corruna</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanata</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Niagara Falls</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pointe Claire</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trois Rivieres</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brnho</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Caslav</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jablonec nad Nisou</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kutna Hora</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rychnov nad Kneznou</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>ÄŒeskÃ© BudÄ›jovice</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bramsche</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Koln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monchengladbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Munster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>MÃ¼nchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Neuss</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osnabruck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wesel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wuppertal</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Csorna</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tatabanya</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rzeszow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tarnow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zabrze</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zawadzkie</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barnaul</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stavropol</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bardejov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Martin</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poprad</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2012</study_first_submitted>
  <study_first_submitted_qc>June 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2012</study_first_posted>
  <results_first_submitted>March 28, 2018</results_first_submitted>
  <results_first_submitted_qc>April 30, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 14, 2018</results_first_posted>
  <disposition_first_submitted>July 26, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>July 26, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">July 28, 2017</disposition_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cat allergy</keyword>
  <keyword>Rhinoconjunctivitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cat-PAD Treatment 1 (1 Course)</title>
          <description>Cat-PAD Treatment 1
Cat-PAD: 1 dose every 4 weeks Placebo: 1 dose every 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>Cat-PAD Treatment 2 (2 Courses)</title>
          <description>Cat-PAD Treatment regimen 2
Cat-PAD: 1 dose every 4 weeks</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo
Placebo: 1 dose every 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="468"/>
                <participants group_id="P2" count="470"/>
                <participants group_id="P3" count="470"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="420"/>
                <participants group_id="P2" count="412"/>
                <participants group_id="P3" count="417"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="53"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject deterioration</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-specified</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Use of prohibted therapies</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cat-PAD Treatment 1 (1 Course)</title>
          <description>Cat-PAD Treatment 1
Cat-PAD: 1 dose every 4 weeks Placebo: 1 dose every 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>Cat-PAD Treatment 2 (2 Courses)</title>
          <description>Cat-PAD Treatment regimen 2
Cat-PAD: 1 dose every 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo
Placebo: 1 dose every 4 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="468"/>
            <count group_id="B2" value="470"/>
            <count group_id="B3" value="470"/>
            <count group_id="B4" value="1408"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="439"/>
                    <measurement group_id="B2" value="441"/>
                    <measurement group_id="B3" value="438"/>
                    <measurement group_id="B4" value="1318"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="301"/>
                    <measurement group_id="B2" value="317"/>
                    <measurement group_id="B3" value="317"/>
                    <measurement group_id="B4" value="935"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="167"/>
                    <measurement group_id="B2" value="153"/>
                    <measurement group_id="B3" value="153"/>
                    <measurement group_id="B4" value="473"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="458"/>
                    <measurement group_id="B2" value="468"/>
                    <measurement group_id="B3" value="463"/>
                    <measurement group_id="B4" value="1389"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Combined Score in Cat-PAD Treatment Groups Compared With Placebo</title>
        <description>The primary endpoint was the mean Combined Score (CS) during the Post Administration Collection Period 3 (52-54 weeks after randomisation) in the Cat-PAD treatment groups compared with the mean CS in the placebo group.
CS = Total Rhinoconjunctivitis Symptom Score (TRSS) (0-24/8) + Rescue Medication Score (RMS) (0-3). Eight symptoms are defined in the TRSS, 4 nasal symptoms: runny nose, sneezing; blocked nose, and itchy nose and 4 ocular symptoms: itchy eyes; watery eyes; red eyes, and sore eyes. Each symptom was rated in severity on a score of 0-3 (0=absent, 3=severe) and the TRSS was divided by the number of symptoms (8) to provide an average score per symptom of 0-3.
For RMS the score was allocated according Didier et al where RMS = 0 (no allergy rescue medication use per day) to RMS = 3 (at least one dose of systemic corticosteroid per day). The RMS score was not additive, and therefore the maximum RMS was 3 and the maximum CS was 6.</description>
        <time_frame>52-54 weeks after randomisation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cat-PAD Treatment 1 (1 Course)</title>
            <description>Cat-PAD Treatment 1
Cat-PAD: 1 dose every 4 weeks Placebo: 1 dose every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Cat-PAD Treatment 2 (2 Courses)</title>
            <description>Cat-PAD Treatment regimen 2
Cat-PAD: 1 dose every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo
Placebo: 1 dose every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Combined Score in Cat-PAD Treatment Groups Compared With Placebo</title>
          <description>The primary endpoint was the mean Combined Score (CS) during the Post Administration Collection Period 3 (52-54 weeks after randomisation) in the Cat-PAD treatment groups compared with the mean CS in the placebo group.
CS = Total Rhinoconjunctivitis Symptom Score (TRSS) (0-24/8) + Rescue Medication Score (RMS) (0-3). Eight symptoms are defined in the TRSS, 4 nasal symptoms: runny nose, sneezing; blocked nose, and itchy nose and 4 ocular symptoms: itchy eyes; watery eyes; red eyes, and sore eyes. Each symptom was rated in severity on a score of 0-3 (0=absent, 3=severe) and the TRSS was divided by the number of symptoms (8) to provide an average score per symptom of 0-3.
For RMS the score was allocated according Didier et al where RMS = 0 (no allergy rescue medication use per day) to RMS = 3 (at least one dose of systemic corticosteroid per day). The RMS score was not additive, and therefore the maximum RMS was 3 and the maximum CS was 6.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="417"/>
                <count group_id="O2" value="414"/>
                <count group_id="O3" value="414"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" spread="0.068"/>
                    <measurement group_id="O2" value="1.00" spread="0.068"/>
                    <measurement group_id="O3" value="1.05" spread="0.068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean TRSS</title>
        <description>Mean Total Rhinoconjunctivitis Symptom Score (TRSS) in Cat-PAD treatment groups compared with placebo.
Eight symptoms are defined in the TRSS, 4 nasal symptoms: runny nose, sneezing; blocked nose, and itchy nose and 4 ocular symptoms: itchy eyes; watery eyes; red eyes, and sore eyes. Each symptom was rated in severity on a score of 0-3 (0. absent; 1. mild, barely noticeable; 2. moderate, annoying/troublesome; 3. severe, very annoying/very troublesome), therefore TRSS could range from 0 to 24. Higher TRSS reflected more severe symptom scores. Symptoms were scored daily for a period of approximately 3 weeks. 52-54 weeks after randomisation.</description>
        <time_frame>52-54 weeks after randomisation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cat-PAD Treatment 1 (1 Course)</title>
            <description>Cat-PAD Treatment 1
Cat-PAD: 1 dose every 4 weeks Placebo: 1 dose every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Cat-PAD Treatment 2 (2 Courses)</title>
            <description>Cat-PAD Treatment regimen 2
Cat-PAD: 1 dose every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo
Placebo: 1 dose every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean TRSS</title>
          <description>Mean Total Rhinoconjunctivitis Symptom Score (TRSS) in Cat-PAD treatment groups compared with placebo.
Eight symptoms are defined in the TRSS, 4 nasal symptoms: runny nose, sneezing; blocked nose, and itchy nose and 4 ocular symptoms: itchy eyes; watery eyes; red eyes, and sore eyes. Each symptom was rated in severity on a score of 0-3 (0. absent; 1. mild, barely noticeable; 2. moderate, annoying/troublesome; 3. severe, very annoying/very troublesome), therefore TRSS could range from 0 to 24. Higher TRSS reflected more severe symptom scores. Symptoms were scored daily for a period of approximately 3 weeks. 52-54 weeks after randomisation.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="417"/>
                <count group_id="O2" value="414"/>
                <count group_id="O3" value="414"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.67" spread="0.358"/>
                    <measurement group_id="O2" value="5.54" spread="0.356"/>
                    <measurement group_id="O3" value="5.87" spread="0.357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Daily TNSS in Cat-PAD Compared With Placebo</title>
        <description>TNSS (Total nasal symptom score) was the sum of all the nasal symptom scores (runny nose; sneezing; blocked nose; itchy nose) and could range from 0 to 12. Higher TNSS reflected more severe symptoms.
Subjects rated the severity of each symptom over the last 24 hours as follows: 0. absent; 1. mild, barely noticeable; 2. moderate, annoying/troublesome; 3. severe, very annoying/very troublesome. Symptoms were scored daily for a period of approximately 3 weeks. 52-54 weeks after randomisation.</description>
        <time_frame>52-54 weeks after randomisation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cat-PAD Treatment 1 (1 Course)</title>
            <description>Cat-PAD Treatment 1
Cat-PAD: 1 dose every 4 weeks Placebo: 1 dose every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Cat-PAD Treatment 2 (2 Courses)</title>
            <description>Cat-PAD Treatment regimen 2
Cat-PAD: 1 dose every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo
Placebo: 1 dose every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Daily TNSS in Cat-PAD Compared With Placebo</title>
          <description>TNSS (Total nasal symptom score) was the sum of all the nasal symptom scores (runny nose; sneezing; blocked nose; itchy nose) and could range from 0 to 12. Higher TNSS reflected more severe symptoms.
Subjects rated the severity of each symptom over the last 24 hours as follows: 0. absent; 1. mild, barely noticeable; 2. moderate, annoying/troublesome; 3. severe, very annoying/very troublesome. Symptoms were scored daily for a period of approximately 3 weeks. 52-54 weeks after randomisation.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="417"/>
                <count group_id="O2" value="414"/>
                <count group_id="O3" value="414"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.48" spread="0.197"/>
                    <measurement group_id="O2" value="3.36" spread="0.196"/>
                    <measurement group_id="O3" value="3.44" spread="0.196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Daily TOSS in Cat-PAD Compared to Placebo</title>
        <description>Mean daily Total Ocular Symptom Score (TOSS) in Cat-PAD treatment groups compared to placebo groups
TOSS was the sum of all the ocular symptom scores (itchy eyes; watery eyes; red eyes; sore eyes) and could range from 0 to 12. Higher TOSS reflected more severe symptoms.
Subjects rated the severity of each symptom over the last 24 hours as follows: 0. absent; 1. mild, barely noticeable; 2. moderate, annoying/troublesome; 3. severe, very annoying/very troublesome. Symptoms were scored daily for a period of approximately 3 weeks. 52-54 weeks after randomisation.</description>
        <time_frame>52-54 weeks after randomisation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cat-PAD Treatment 1 (1 Course)</title>
            <description>Cat-PAD Treatment 1
Cat-PAD: 1 dose every 4 weeks Placebo: 1 dose every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Cat-PAD Treatment 2 (2 Courses)</title>
            <description>Cat-PAD Treatment regimen 2
Cat-PAD: 1 dose every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo
Placebo: 1 dose every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Daily TOSS in Cat-PAD Compared to Placebo</title>
          <description>Mean daily Total Ocular Symptom Score (TOSS) in Cat-PAD treatment groups compared to placebo groups
TOSS was the sum of all the ocular symptom scores (itchy eyes; watery eyes; red eyes; sore eyes) and could range from 0 to 12. Higher TOSS reflected more severe symptoms.
Subjects rated the severity of each symptom over the last 24 hours as follows: 0. absent; 1. mild, barely noticeable; 2. moderate, annoying/troublesome; 3. severe, very annoying/very troublesome. Symptoms were scored daily for a period of approximately 3 weeks. 52-54 weeks after randomisation.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="417"/>
                <count group_id="O2" value="414"/>
                <count group_id="O3" value="414"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.20" spread="0.179"/>
                    <measurement group_id="O2" value="2.19" spread="0.178"/>
                    <measurement group_id="O3" value="2.42" spread="0.179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean RMS in Cat-PAD Compared With Placebo</title>
        <description>Mean RMS (Rescue medication score) in Cat-PAD treatment groups compared with placebo groups.
The use of rhinoconjunctivitis rescue medications was recorded by the subject on a daily basis just before bedtime for approximately 21 days, 52-54 weeks after randomisation and was scored based on a previously published system as follows: 0 = no allergy rescue medication used per day; 0.5 = at least one dose of antihistamine eye drops used per day; 1 = at least one dose of oral antihistamine used per day; 2 = at least one dose of intranasal corticosteroid used per day; 3 = at least one dose of systemic corticosteroid used per day. The score was according to the highest level of rescue medication used and was not additive.</description>
        <time_frame>52-54 weeks after randomisation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cat-PAD Treatment 1 (1 Course)</title>
            <description>Cat-PAD Treatment 1
Cat-PAD: 1 dose every 4 weeks Placebo: 1 dose every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Cat-PAD Treatment 2 (2 Courses)</title>
            <description>Cat-PAD Treatment regimen 2
Cat-PAD: 1 dose every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo
Placebo: 1 dose every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean RMS in Cat-PAD Compared With Placebo</title>
          <description>Mean RMS (Rescue medication score) in Cat-PAD treatment groups compared with placebo groups.
The use of rhinoconjunctivitis rescue medications was recorded by the subject on a daily basis just before bedtime for approximately 21 days, 52-54 weeks after randomisation and was scored based on a previously published system as follows: 0 = no allergy rescue medication used per day; 0.5 = at least one dose of antihistamine eye drops used per day; 1 = at least one dose of oral antihistamine used per day; 2 = at least one dose of intranasal corticosteroid used per day; 3 = at least one dose of systemic corticosteroid used per day. The score was according to the highest level of rescue medication used and was not additive.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="417"/>
                <count group_id="O2" value="414"/>
                <count group_id="O3" value="414"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" spread="0.038"/>
                    <measurement group_id="O2" value="0.31" spread="0.037"/>
                    <measurement group_id="O3" value="0.32" spread="0.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean RQLQ Score in Cat-PAD Compared With Placebo</title>
        <description>The RQLQ (Rhinoconjunctivitis Quality of Life Questionnaire) was completed by subjects at the end of the study (52-54 weeks after randomisation).
The RQLQ is a validated method of assessing quality of life and has 28 questions in seven domains (activity limitation, sleep problems, nasal symptoms, eye symptoms, non-nasal/eye symptoms, practical problems and emotional function). Subjects recalled how their rhinoconjunctivitis had been during the last week and responded to each question on a seven-point scale (0 = no impairment, 6 = maximum impairment). The questions were equally weighted, and the RQLQ score was the mean of the 28 questions and could range from zero to six.</description>
        <time_frame>52-54 weeks after randomisation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cat-PAD Treatment 1 (1 Course)</title>
            <description>Cat-PAD Treatment 1
Cat-PAD: 1 dose every 4 weeks Placebo: 1 dose every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Cat-PAD Treatment 2 (2 Courses)</title>
            <description>Cat-PAD Treatment regimen 2
Cat-PAD: 1 dose every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo
Placebo: 1 dose every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean RQLQ Score in Cat-PAD Compared With Placebo</title>
          <description>The RQLQ (Rhinoconjunctivitis Quality of Life Questionnaire) was completed by subjects at the end of the study (52-54 weeks after randomisation).
The RQLQ is a validated method of assessing quality of life and has 28 questions in seven domains (activity limitation, sleep problems, nasal symptoms, eye symptoms, non-nasal/eye symptoms, practical problems and emotional function). Subjects recalled how their rhinoconjunctivitis had been during the last week and responded to each question on a seven-point scale (0 = no impairment, 6 = maximum impairment). The questions were equally weighted, and the RQLQ score was the mean of the 28 questions and could range from zero to six.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="396"/>
                <count group_id="O2" value="403"/>
                <count group_id="O3" value="393"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26" spread="0.080"/>
                    <measurement group_id="O2" value="1.26" spread="0.079"/>
                    <measurement group_id="O3" value="1.25" spread="0.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days With no Moderate or Severe TRSS Symptoms Without Rescue Medication Use</title>
        <description>The number of well days, i.e., days with no moderately or severely annoying symptoms and with no rescue medication used was calculated for all subjects over a period of approximately 21 days, 52-54 weeks after randomisation.</description>
        <time_frame>52-54 week after randomisaiton</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cat-PAD Treatment 1 (1 Course)</title>
            <description>Cat-PAD Treatment 1
Cat-PAD: 1 dose every 4 weeks Placebo: 1 dose every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Cat-PAD Treatment 2 (2 Courses)</title>
            <description>Cat-PAD Treatment regimen 2
Cat-PAD: 1 dose every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo
Placebo: 1 dose every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days With no Moderate or Severe TRSS Symptoms Without Rescue Medication Use</title>
          <description>The number of well days, i.e., days with no moderately or severely annoying symptoms and with no rescue medication used was calculated for all subjects over a period of approximately 21 days, 52-54 weeks after randomisation.</description>
          <units>days</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="417"/>
                <count group_id="O2" value="414"/>
                <count group_id="O3" value="414"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.44" spread="0.56"/>
                    <measurement group_id="O2" value="10.11" spread="0.556"/>
                    <measurement group_id="O3" value="9.76" spread="0.557"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 52 weeks after randomisation</time_frame>
      <desc>The number of participants at risk for AEs and SAEs is for the safety population, one participant withdrew after randomisation but before receiving any treatment and is therefore included in the ITT population and therefore in the participant flow module but is not included in the safety population. The data presented reflects the data in the TLFs and as written in the Clinical Study Report.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cat-PAD Treatment 1 (1 Course)</title>
          <description>Cat-PAD Treatment 1
Cat-PAD: 1 dose every 4 weeks Placebo: 1 dose every 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>Cat-PAD Treatment 2 (2 Courses)</title>
          <description>Cat-PAD Treatment regimen 2
Cat-PAD: 1 dose every 4 weeks</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo
Placebo: 1 dose every 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="467"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="470"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="470"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypthyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="470"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="470"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="470"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="470"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="470"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="470"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="470"/>
              </event>
              <event>
                <sub_title>Scrotal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="470"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="470"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="470"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="470"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="470"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="470"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="470"/>
              </event>
              <event>
                <sub_title>Comminuted fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="470"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="470"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="470"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="470"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="470"/>
              </event>
              <event>
                <sub_title>Femoroacetabular impingement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="470"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="470"/>
              </event>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="470"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="470"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="470"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="470"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="470"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydonephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="470"/>
              </event>
              <event>
                <sub_title>IgA nephropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="470"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="470"/>
              </event>
              <event>
                <sub_title>Pneumothorax spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="470"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="470"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="470"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="470"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="298" subjects_at_risk="467"/>
                <counts group_id="E2" subjects_affected="299" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="305" subjects_at_risk="470"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="467"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="470"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="470"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="467"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="470"/>
                <counts group_id="E3" events="15" subjects_affected="12" subjects_at_risk="470"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="470"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="470"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="51" subjects_affected="19" subjects_at_risk="467"/>
                <counts group_id="E2" events="45" subjects_affected="13" subjects_at_risk="470"/>
                <counts group_id="E3" events="41" subjects_affected="11" subjects_at_risk="470"/>
              </event>
              <event>
                <sub_title>Injection site urticaria</sub_title>
                <counts group_id="E1" events="95" subjects_affected="17" subjects_at_risk="467"/>
                <counts group_id="E2" events="43" subjects_affected="9" subjects_at_risk="470"/>
                <counts group_id="E3" events="41" subjects_affected="7" subjects_at_risk="470"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="467"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="470"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="470"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to animal</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="467"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="470"/>
                <counts group_id="E3" events="13" subjects_affected="11" subjects_at_risk="470"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="124" subjects_affected="85" subjects_at_risk="467"/>
                <counts group_id="E2" events="128" subjects_affected="87" subjects_at_risk="470"/>
                <counts group_id="E3" events="127" subjects_affected="90" subjects_at_risk="470"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="48" subjects_affected="37" subjects_at_risk="467"/>
                <counts group_id="E2" events="41" subjects_affected="34" subjects_at_risk="470"/>
                <counts group_id="E3" events="60" subjects_affected="42" subjects_at_risk="470"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="26" subjects_affected="21" subjects_at_risk="467"/>
                <counts group_id="E2" events="29" subjects_affected="24" subjects_at_risk="470"/>
                <counts group_id="E3" events="24" subjects_affected="23" subjects_at_risk="470"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="27" subjects_affected="23" subjects_at_risk="467"/>
                <counts group_id="E2" events="25" subjects_affected="23" subjects_at_risk="470"/>
                <counts group_id="E3" events="21" subjects_affected="19" subjects_at_risk="470"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="467"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="470"/>
                <counts group_id="E3" events="17" subjects_affected="14" subjects_at_risk="470"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="467"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="470"/>
                <counts group_id="E3" events="20" subjects_affected="19" subjects_at_risk="470"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="467"/>
                <counts group_id="E2" events="16" subjects_affected="12" subjects_at_risk="470"/>
                <counts group_id="E3" events="13" subjects_affected="11" subjects_at_risk="470"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="467"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="470"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="470"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="467"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="470"/>
                <counts group_id="E3" events="13" subjects_affected="10" subjects_at_risk="470"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="20" subjects_affected="12" subjects_at_risk="467"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="470"/>
                <counts group_id="E3" events="20" subjects_affected="15" subjects_at_risk="470"/>
              </event>
              <event>
                <sub_title>Athralgia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="467"/>
                <counts group_id="E2" events="16" subjects_affected="12" subjects_at_risk="470"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="470"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="78" subjects_affected="25" subjects_at_risk="467"/>
                <counts group_id="E2" events="86" subjects_affected="39" subjects_at_risk="470"/>
                <counts group_id="E3" events="76" subjects_affected="35" subjects_at_risk="470"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="26" subjects_affected="18" subjects_at_risk="467"/>
                <counts group_id="E2" events="27" subjects_affected="18" subjects_at_risk="470"/>
                <counts group_id="E3" events="26" subjects_affected="24" subjects_at_risk="470"/>
              </event>
              <event>
                <sub_title>Orophayngeal pai</sub_title>
                <counts group_id="E1" events="20" subjects_affected="16" subjects_at_risk="467"/>
                <counts group_id="E2" events="20" subjects_affected="16" subjects_at_risk="470"/>
                <counts group_id="E3" events="18" subjects_affected="16" subjects_at_risk="470"/>
              </event>
              <event>
                <sub_title>Athma</sub_title>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="467"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="470"/>
                <counts group_id="E3" events="17" subjects_affected="16" subjects_at_risk="470"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="19" subjects_affected="12" subjects_at_risk="467"/>
                <counts group_id="E2" events="13" subjects_affected="7" subjects_at_risk="470"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="470"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>To avoid disclosures that may affect the proprietary rights of the Sponsor, the Investigator agrees to allow Circassia the opportunity to review all manuscripts and abstracts 60 days prior to submission for publication. Circassia reserves the right to include the report of this study in any regulatory documentation or submission or in any informational materials.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>VP Clinical Operations</name_or_title>
      <organization>Circassia Ltd</organization>
      <phone>+44 1865 405560</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

